Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Francesca Romana Mauro, MD PhD, Gianluigi Reda, MD, Valentina Arena, MS, Livio Trentin, MD, Marta Coscia, MD PhD, Paolo Sportoletti, MD, Luca Laurenti, MD, Gianluca Gaidano, Roberto Marasca, MD, Lorella Orsucci, MD, Roberta Murru, MD, Caterina Stelitano, Fiorella Ilariucci, MD, Donato Mannina, MD, Massimo Massaia, MD, Gian Matteo Rigolin, Lydia Scarfo, Monia Marchetti, MD, Luciano Levato, MD, Monica Tani, MD, Annalisa Arcari, MD, Gerardo Musuraca, MD, Marina Deodato, Piero Galieni, Catello Califano, MD, Daniela Gottardi, MD, Anna Marina Liberati, MD, Daniela Pietrasanta, MD, Stefano Molica, MD, Ramona Cassin, MD, Andrea Visentin, MDPhD, Candida Vitale, MDPhD, Gianfranco Lapietra, MD, Irene Della Starza, PhD, Maria Stefania De Propris, PhD, Sara Raponi, PhD, Mauro Nanni, PhD, Ilaria Del Giudice, MD PhD, Giorgia Giuliani, PhD, Marco Vignetti, MD, Anna Guarini, PhD, Francesco Albano, Antonino Neri, MD, Antonio Cuneo, MD, Robin Foà, MD

Blood (2020) 136 (Supplement 1): 47–49.

https://doi.org/10.1182/blood-2020-135922

Published: 2020

Journal Articles

Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Α Training/Validation Study

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-136389

Published: 2020

Journal Articles

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Alessandro Pulsoni, MD, Irene Della Starza, PhD, Maria Elena Tosti, statistician, Luca Vincenzo Cappelli, Giorgia Annechini, Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Gianna Maria D'Elia, Lavinia Grapulin, MD, Anna Guarini, Ilaria Del Giudice, MD PhD, Robin Foa

Blood (2016) 128 (22): 2959.

https://doi.org/10.1182/blood.V128.22.2959.2959

Published: 2016

Journal Articles

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Marzia Cavalli, PhD, Lucia Anna De Novi, PhD, Irene Della Starza, PhD, Luca Cappelli, Vittorio Nunes, Alessandro Pulsoni, MD, Ilaria Del Giudice, MD PhD, Anna Guarini, Robin Foa

Blood (2016) 128 (22): 5308.

https://doi.org/10.1182/blood.V128.22.5308.5308

Published: 2016

Journal Articles

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

Blood (2015) 126 (23): 2946.

https://doi.org/10.1182/blood.V126.23.2946.2946

Published: 2015

Journal Articles

BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

Blood (2014) 124 (21): 3295.

https://doi.org/10.1182/blood.V124.21.3295.3295

Published: 2014

Journal Articles

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Sabina Chiaretti, MD, PhD, Marilisa Marinelli, PhD, Ilaria Del Giudice, MD, PhD, Silvia Bonina, PhD student, Sara Gabrielli, Miss, Alfonso Piciocchi, Monica Messina, PhD, Marco Vignetti, MD, Davide Rossi, MD, PhD, Valeria Di Maio, Miss, Francesca Romana Mauro, MD, Anna Guarini, PhD, Gianluca Gaidano, MD, PhD, Robin Foà, MD

Blood (2012) 120 (21): 1784.

https://doi.org/10.1182/blood.V120.21.1784.1784

Published: 2012

Journal Articles

Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.

Simona Tavolaro, BS, Sabina Chiaretti, MD, PhD, Monica Messina, BS, Nadia Peragine, BS, Roberta Maggio, BS, Ilaria Del Giudice, MD, PhD, Emanuela M. Ghia, PhD, Francesca R. Mauro, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2007) 110 (11): 3117.

https://doi.org/10.1182/blood.V110.11.3117.3117

Published: 2007

Journal Articles

IgV H Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

Simona Tavolaro, BS, Roberta Maggio, BS, Nadia Peragine, BS, Monica Messina, BS, Franca Citarella, PhD, Simona Santangelo Miss, Marilisa Marinelli, BS, Maria R. Ricciardi, PhD, Maria S. De Propris, PhD, Ilaria Del Giudice, MD, PhD, Francesca R. Mauro, MD, Sabina Chiaretti, MD, PhD, Robert Foa, MD, Anna Guarini, PhD

Blood (2007) 110 (11): 1133.

https://doi.org/10.1182/blood.V110.11.1133.1133

Published: 2007

Journal Articles

Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.

Simona Tavolaro, BS, Sabina Chiaretti, MD, PhD, Monica Messina, BS, Francesca R. Mauro, MD, Ilaria Del Giudice, MD PhD, Roberta Maggio, BS, Emanuela M. Ghia, BS, Marilisa Marinelli, BS, Simona Santangelo Miss, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 2794.

https://doi.org/10.1182/blood.V108.11.2794.2794

Published: 2006

Journal Articles

Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.

Ilaria Del Giudice, MD, PhD, Stefano A. Pileri, MD, Maura Rossi, BTD, Elena Sabattini, MD, Cristina Campidelli, MD, Irene Della Starza Miss, Stefania M. De Propris, PhD, Francesca Mancini, PhD, Francesca R. Mauro, MD, Agostino Tafuri, MD, Luisa Bizzoni, MD, Angela Rago, MD, Angela Amendola, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 4612.

https://doi.org/10.1182/blood.V108.11.4612.4612

Published: 2006

Journal Articles

Angiogenic Activity in IgV H Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

Roberta Maggio, BS, Nadia Peragine, BS, Monica Messina, BS, Sabina Chiaretti, MD PhD, Stefania M. De Propris, PhD, Simona Tavolaro, BS, Marilisa Marinelli, BS, Elisabetta Calabrese, BS, Ilaria Del Giudice, MD PhD, Francesca R. Mauro, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 2819.

https://doi.org/10.1182/blood.V108.11.2819.2819

Published: 2006

Journal Articles

Chronic Lymphocytic Leukemia (CLL) with Discordance in ZAP-70 Expression and IgVH Mutation Status.

Ilaria Del Giudice, MD, PhD, Emanuela M. Ghia, BS, Stefania M. De Propris, PhD, Marilisa Marinelli, BS, Mauro Nanni, PhD, Francesca Mancini, PhD, Massimo Gentile, MD, Elena Giammartini, MD, Elisabetta Calabrese, MD, Francesca R. Mauro, MD, Anna Guarini, PhD, Robert Foa, MD

Blood (2006) 108 (11): 2787.

https://doi.org/10.1182/blood.V108.11.2787.2787

Published: 2006

NARROW

Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'

Mutations of the Exportin 1 (XPO1) Gene Predict Shorter Time to First Treatment in 1092 Early Stage Chronic Lymphocytic Leukemia Patients. Α Training/Validation Study

Early Stage Follicular Lymphoma. Predictive Role of Minimal Residual Disease (MRD) and Impact of MRD-Driven Treatment with Radiotherapy and Rituximab on Clinical Outcome

Comparative Analysis Between RQ-PCR and Digital Droplet PCR of BCL2/IGH Rearrangement in the Peripheral Blood and Bone Marrow of Early Stage Follicular Lymphoma

Fludarabine, Cyclophosphamide, Ofatumumab (FC-O2) As Front-Line Treatment for Young and Fit Patients with Chronic Lymphocytic Leukemia (CLL): Preliminary Results of the Prospective Phase 2 LLC0911 Gimema Study

BIRC3 disruption and Copy Number Aberrations in Chronic Lymphocytic Leukemia (CLL) Patients with 11q Deletion

NOTCH1 , SF3B1 and BIRC3 Mutations in Chronic Lymphocytic Leukemia (CLL) Patients Requiring First-LINE Treatment: Correlation with Biological Parameters and Response to Treatment

Gene Expression Profile Reveals a Unique Pattern of Protein Kinases in Chronic Lymphocytic Leukemia (CLL): Potential Role of the Second Generation Protein Kinase Inhibitors.

IgV H Germline and Mutated Chronic Lymphocytic Leukemia (CLL) Cases Exert a Diverse Responsiveness upon BCR Ligation.

Gene Expression Profile of Protein Kinases Reveals a Distinctive Signature of Chronic Lymphocytic Leukemia (CLL) and Points to a Role of Second Generation Protein Kinase Inhibitors.

Histopathologic and Molecular Features of Persistent Polyclonal B-Cell Lymphocytosis Challenging the Benign Nature of the Disorder.

Angiogenic Activity in IgV H Mutated and Unmutated Chronic Lymphocytic Leukemia (CLL): Indications for the Therapeutic Use of VEGF-Signaling Inhibitors.

Chronic Lymphocytic Leukemia (CLL) with Discordance in ZAP-70 Expression and IgVH Mutation Status.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only